BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor modelsUlrike Rauh, Todd R. Golub, Nicolas D. Werbeck et al.|Nature Cancer|2024Cited by 28
ANJ810 is a novel highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor modelsUlrike Rauh, Todd R. Golub, Guo Wei et al.|Research Square|2023Cited by 1
Abstract LB_A01: Rapidly cleared MCL1 inhibitor TTX-810 showing robust efficacy in preclinical tumor models with no effects on cardiomyocytes in vitro and in vivoUlrike Rauh, Todd R. Golub, Virendar K. Kaushik et al.|Molecular Cancer Therapeutics|2023Cited by 1
Abstract B174: The non-covalent HCK/BTK inhibitor TTX-114 displays potent <i>in vitro</i> and <i>in vivo</i> anti-tumor activity in leukemia and lymphomaUlrike Rauh, Brian K. Hubbard, Michael H. Serrano‐Wu et al.|Molecular Cancer Therapeutics|2023Cited by 0